Literature DB >> 22343747

Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment.

Yuji Yamanashi1, Tohru Tezuka, Kazumasa Yokoyama.   

Abstract

It is widely accepted that receptor protein-tyrosine kinases (RTKs) are activated upon dimerization by binding to their extracellular ligands. However, EGF receptor (EGFR) dimerization per se does not require ligand binding. Instead, its cytoplasmic kinase domains have to form characteristic head-to-tail asymmetric dimers to become active, where one 'activator' domain activates the other 'receiver' domain. The non-catalytic, cytoplasmic regions of RTKs, namely the juxtamembrane and carboxy terminal portions, also regulate kinase activity. For instance, the juxtamembrane region of the RTK MuSK inhibits the kinase domain probably together with a cellular factor(s). These findings suggest that RTKs could be activated by cytoplasmic proteins. Indeed, Dok-7 and cytohesin have recently been identified as such activators of MuSK and EGFR, respectively. Given that failure of Dok-7 signaling causes myasthenia, and inhibition of cytohesin signaling reduces the proliferation of EGFR-dependent cancer cells, cytoplasmic activators of RTKs may provide new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343747     DOI: 10.1093/jb/mvs013

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

Review 1.  Practical Anatomy of the Neuromuscular Junction in Health and Disease.

Authors:  Hiroshi Nishimune; Kazuhiro Shigemoto
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 2.  Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis.

Authors:  Huimin Hu; Yanwei Liu; Tao Jiang
Journal:  Tumour Biol       Date:  2015-03-07

3.  Regulation of chandelier cell cartridge and bouton development via DOCK7-mediated ErbB4 activation.

Authors:  Yilin Tai; Justyna A Janas; Chia-Lin Wang; Linda Van Aelst
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

4.  HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.

Authors:  Z Hartman; H Zhao; Y M Agazie
Journal:  Oncogene       Date:  2012-10-01       Impact factor: 9.867

5.  Facile supermolecular aptamer inhibitors of L-selectin.

Authors:  Elizabeth K Chang; Mark A Eckert; M Monsur Ali; Hamidreza Riazifar; Egest J Pone; Linan Liu; Weian Zhao
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

6.  The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  MACF1 links Rapsyn to microtubule- and actin-binding proteins to maintain neuromuscular synapses.

Authors:  Julien Oury; Yun Liu; Ana Töpf; Slobodanka Todorovic; Esthelle Hoedt; Veeramani Preethish-Kumar; Thomas A Neubert; Weichun Lin; Hanns Lochmüller; Steven J Burden
Journal:  J Cell Biol       Date:  2019-03-06       Impact factor: 10.539

8.  Vezatin is required for the maturation of the neuromuscular synapse.

Authors:  Natasha Koppel; Matthew B Friese; Helene L Cardasis; Thomas A Neubert; Steven J Burden
Journal:  Mol Biol Cell       Date:  2019-08-14       Impact factor: 4.138

9.  Receptor tyrosine kinases: molecular switches regulating CNS axon regeneration.

Authors:  Vasanthy Vigneswara; Sarina Kundi; Zubair Ahmed
Journal:  J Signal Transduct       Date:  2012-07-16

10.  A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia.

Authors:  Asma Ben Ammar; Payam Soltanzadeh; Stéphanie Bauché; Pascale Richard; Evelyne Goillot; Ruth Herbst; Karen Gaudon; Caroline Huzé; Laurent Schaeffer; Yuji Yamanashi; Osamu Higuchi; Antoine Taly; Jeanine Koenig; Jean-Paul Leroy; Fayçal Hentati; Hossein Najmabadi; Kimia Kahrizi; Manouchehr Ilkhani; Michel Fardeau; Bruno Eymard; Daniel Hantaï
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.